News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
274,058 Results
Type
Article (14315)
Company Profile (105)
Press Release (259630)
Multimedia
Podcasts (66)
Webinars (13)
Section
Business (88281)
Career Advice (465)
Deals (15393)
Drug Delivery (73)
Drug Development (36749)
Employer Resources (50)
FDA (6390)
Job Trends (6233)
News (150749)
Policy (14148)
Tag
2027 Genetown Elite (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (445)
Accelerated approval (14)
Adcomms (8)
Allergies (71)
Alliances (23317)
ALS (69)
Alzheimer's disease (482)
Antibody-drug conjugate (ADC) (102)
Approvals (6576)
Artificial intelligence (204)
Autoimmune disease (46)
Automation (13)
Bankruptcy (150)
Best Places to Work (4370)
BIOSECURE Act (9)
Biosimilars (120)
Biotechnology (40)
Bladder cancer (38)
Brain cancer (30)
Breast cancer (174)
Cancer (1333)
Cardiovascular disease (154)
Career advice (418)
Career pathing (13)
CAR-T (51)
CDC (6)
Cell therapy (159)
Cervical cancer (9)
Clinical research (32056)
Collaboration (743)
Compensation (329)
Complete response letters (34)
COVID-19 (780)
CRISPR (45)
C-suite (449)
Cystic fibrosis (58)
Data (1844)
Denatured (18)
Depression (46)
Diabetes (127)
Diagnostics (1385)
Digital health (10)
Diversity (2)
Diversity, equity & inclusion (14)
Drug discovery (121)
Drug pricing (114)
Drug shortages (12)
Duchenne muscular dystrophy (82)
Earnings (33510)
Editorial (23)
Employer branding (4)
Employer resources (46)
Events (39011)
Executive appointments (537)
FDA (7496)
Fibrodysplasia Ossificans Progressiva (3)
Friedreich's ataxia (2)
Frontotemporal dementia (1)
Funding (439)
Gene editing (73)
Generative AI (18)
Gene therapy (169)
GLP-1 (443)
Government (1406)
Grass and pollen (4)
Guidances (164)
Healthcare (3579)
HIV (12)
Huntington's disease (10)
IgA nephropathy (39)
Immunology and inflammation (69)
Immuno-oncology (15)
Indications (55)
Infectious disease (847)
Inflammatory bowel disease (74)
Inflation Reduction Act (7)
Influenza (25)
Intellectual property (115)
Interviews (60)
IPO (5913)
IRA (33)
Job creations (2055)
Job search strategy (374)
JPM (29)
Kidney cancer (9)
Labor market (28)
Layoffs (205)
Leadership (8)
Legal (3450)
Liver cancer (22)
Longevity (8)
Lung cancer (184)
Lymphoma (124)
Machine learning (13)
Management (17)
Manufacturing (420)
MASH (70)
Medical device (1303)
Medtech (1310)
Mergers & acquisitions (9904)
Metabolic disorders (442)
Multiple sclerosis (48)
NASH (14)
Neurodegenerative disease (88)
Neuropsychiatric disorders (39)
Neuroscience (908)
Neurotech (1)
NextGen: Class of 2026 (1588)
Non-profit (605)
Now hiring (18)
Obesity (231)
Opinion (142)
Ovarian cancer (39)
Pain (110)
Pancreatic cancer (52)
Parkinson's disease (80)
Partnered (11)
Patents (224)
Patient recruitment (121)
Peanut (12)
People (29778)
Pharmaceutical (63)
Pharmacy benefit managers (18)
Phase 1 (8313)
Phase 2 (13535)
Phase 3 (12224)
Pipeline (1976)
Policy (135)
Postmarket research (1401)
Preclinical (3344)
Press Release (25)
Prostate cancer (86)
Psychedelics (16)
Radiopharmaceuticals (136)
Rare diseases (357)
Real estate (2659)
Recruiting (19)
Regulatory (10992)
Reports (15)
Research institute (576)
Resumes & cover letters (55)
Rett syndrome (5)
RNA editing (6)
RSV (20)
Schizophrenia (71)
Series A (81)
Series B (53)
Service/supplier (2)
Sickle cell disease (47)
Special edition (10)
Spinal muscular atrophy (81)
Sponsored (9)
Startups (1646)
State (2)
Stomach cancer (5)
Supply chain (49)
Tariffs (68)
The Weekly (46)
Vaccines (238)
Venture capital (33)
Weight loss (142)
Women's health (28)
Worklife (4)
Date
Last 7 days (212)
Last 30 days (682)
Last 365 days (10401)
2026 (1162)
2025 (10719)
2024 (12507)
2023 (14254)
2022 (19574)
2021 (20073)
2020 (19032)
2019 (14885)
2018 (11713)
2017 (13888)
2016 (13129)
2015 (15472)
2014 (12419)
2013 (10592)
2012 (11395)
2011 (11922)
2010 (10888)
Location
Africa (318)
Alabama (19)
Alaska (1)
Arizona (78)
Arkansas (3)
Asia (20908)
Australia (2689)
California (3205)
Canada (1499)
China (561)
Colorado (146)
Connecticut (133)
Delaware (126)
Europe (40908)
Florida (611)
Georgia (63)
Hawaii (1)
Idaho (10)
Illinois (352)
India (45)
Indiana (241)
Iowa (2)
Japan (251)
Kansas (77)
Kentucky (20)
Louisiana (4)
Maine (2)
Maryland (425)
Massachusetts (2621)
Michigan (46)
Minnesota (168)
Mississippi (1)
Missouri (33)
Montana (8)
Nebraska (7)
Nevada (16)
New Hampshire (8)
New Jersey (1414)
New Mexico (7)
New York (913)
North Carolina (628)
North Dakota (2)
Northern California (1460)
Ohio (81)
Oklahoma (5)
Oregon (18)
Pennsylvania (725)
Puerto Rico (13)
Rhode Island (17)
South America (508)
South Carolina (10)
Southern California (1403)
Tennessee (53)
Texas (457)
United States (12813)
Utah (60)
Virginia (161)
Washington D.C. (42)
Washington State (225)
West Virginia (1)
Wisconsin (39)
Wyoming (1)
274,058 Results for "amylyx pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Amylyx Pharmaceuticals Reports Third Quarter 2025 Financial Results
November 7, 2025
·
15 min read
Press Releases
Amylyx Pharmaceuticals to Present at Upcoming Investor Conferences - November 3, 2025
November 3, 2025
·
1 min read
Press Releases
Amylyx Pharmaceuticals Announces Nomination of AMX0318 as a Novel, Long-Acting GLP-1 Receptor Antagonist Development Candidate, Identified in Collaboration with Gubra A/S
January 8, 2026
·
5 min read
Press Releases
Amylyx Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025
October 31, 2025
·
1 min read
Press Releases
Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences
August 26, 2025
·
1 min read
Press Releases
Amylyx Pharmaceuticals Announces New Safety and Tolerability Cohort 1 Data of AMX0114 in ALS from First-in-Human LUMINA Trial
December 8, 2025
·
7 min read
Press Releases
Amylyx Pharmaceuticals Announces Pricing of $175 Million Underwritten Public Offering of Common Stock
September 10, 2025
·
4 min read
Press Releases
Amylyx Pharmaceuticals Reports Second Quarter 2025 Financial Results
August 7, 2025
·
15 min read
Regulatory
FDA Presses Pause on Atara’s Programs, Play on Amylyx’s ALS Assets
The FDA is putting Atara’s active Investigational New Drug applications on hold due to manufacturing concerns at a third-party provider while releasing Amylyx’s investigational ALS therapy from a previous pause.
January 22, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Amylyx Pharmaceuticals to Discontinue ORION Program of AMX0035 for Progressive Supranuclear Palsy (PSP)
August 28, 2025
·
7 min read
1 of 27,406
Next
